Pre-Application Webinar on NCI’s Provocative Questions Relevant to Population Scientists

February 15, 2018: 2:00 – 3:00 p.m. ET

This webinar focused on the following Provocative Questions (PQ):

• PQ-1: What molecular mechanisms influence disease penetrance in individuals who inherit a cancer susceptibility gene?
• PQ-2: How do variations in immune function caused by comorbidities or observed among different populations affect response to cancer therapy?
• PQ-3: Do genetic interactions between germline variations and somatic mutations contribute to differences in tumor evolution or response to therapy?
• PQ-6: How do circadian processes affect tumor development, progression, and response to therapy?
• PQ-10: How do microbiota affect the response to cancer therapies?
• PQ-11: Through what mechanisms do diet and nutritional interventions affect the response to cancer treatment?
• PQ-12: What are the molecular and/or cellular mechanisms that underlie the development of cancer therapy-induced severe adverse sequelae?

The RFAs discussed included the following:

Please note: All of these RFAs have been reissued as “Clinical Trial Optional” funding opportunity announcements.

• RFA-CA-17-017 (R01) reissued as RFA-CA-18-019 (R01)
• RFA-CA-17-018 (R21) reissued as RFA-CA-18-020 (R21)
• RFA-CA-17-019 (R01) reissued as RFA-CA-18-021 (R01)*
• RFA-CA-17-020 (U01) reissued as RFA-CA-18-022 (U01)*
• RFA-CA-17-021 (P01) reissued as RFA-CA-18-023 (P01)*
• RFA-CA-17-022 (P50) reissued as RFA-CA-18-024 (P50)*

*This is a revision application, or competitive supplement, for the award-type listed.

Presenters

Kelly Filipski, PhD, MPH
Program Director
Clinical and Translational Epidemiology Branch

Stefanie Nelson, PhD
Program Director
Genomic Epidemiology Branch

Danielle Carrick, PhD, MHS
Program Director
Genomic Epidemiology Branch

Jill Reedy, PhD, MPH, RD
Program Director
Risk Factor Assessment Branch